Hip
Senior Member
- Messages
- 18,305
A new vaccine in development code named PRV-101 which protects against infection with coxsackievirus B1 to B5 has been demonstrated effective in a phase 1 clinical trial. If this vaccine eventually makes it onto the vaccine schedule, it might help prevent several chronic diseases that have been linked to coxsackievirus B, including ME/CFS and type 1 diabetes.
Persistent enteroviruses such as coxsackievirus B and echovirus that can live long-term in the body have been linked to numerous chronic diseases, including:
Persistent enteroviruses such as coxsackievirus B and echovirus that can live long-term in the body have been linked to numerous chronic diseases, including:
- type 1 diabetes [1]
- ME/CFS [1]
- chronic myocarditis / pericarditis [1]
- dilated cardiomyopathy [1]
- heart valve disease [1]
- Parkinson's disease [1]
- amyotrophic lateral sclerosis (a motor neuron disease) [1] [2]
- Sjogren's syndrome [1]
- ileocecal Crohn's disease [1]